ストックスクリーナーアプリを入手
11.57
2.85%
-0.34
アフターアワーズ：
11.55
-0.02
-0.17%
前日終値:
$11.91
開ける：
$11.98
24時間の取引高:
1.02M
Relative Volume:
0.46
時価総額：
$820.82M
収益：
-
当期純損益:
$-297.11M
株価収益率:
-2.2293
EPS:
-5.19
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
+14.55%
1か月 パフォーマンス:
+20.15%
6か月 パフォーマンス:
+107.35%
1年 パフォーマンス:
-16.40%
1日の値動き範囲:
$11.50
$11.99
1週間の範囲:
$9.82
$12.15
52週間の値動き範囲:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.57 | 716.53M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
RSI and MACD Indicate Shift in Phathom Pharmaceuticals Inc. SentimentJuly 2025 Outlook & Free Real-Time Volume Trigger Notifications - beatles.ru
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN
Phathom Says No Ownership Changes in Frazier Life Sciences Regulatory Filing - MarketScreener
Phathom Pharmaceuticals clarifies no reduction in Frazier ownership - Investing.com
Phathom Pharmaceuticals Clarifies That There Is No - GlobeNewswire
Administrative 13D Filing Update: Phathom Pharmaceuticals Confirms No Reduction in Major Shareholder Stakes - Stock Titan
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Soars 29% But It's A Story Of Risk Vs Reward - 富途牛牛
Published on: 2025-08-17 07:30:13 - metal.it
Insider Sales At Phathom Pharmaceuticals Landed A Good Price - simplywall.st
Quant Models Detect Momentum Reversal in Phathom Pharmaceuticals Inc.Analyst Upgrade & Smart Swing Trading Alerts - sundaytimes.kr
Can Phathom Pharmaceuticals Inc. Bounce Back From Weekly LowJuly 2025 Sentiment & Low Volatility Stock Recommendations - beatles.ru
Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Shareholders Are up 19% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
Chartists Watching For Breakout in Phathom Pharmaceuticals Inc.Price Movement Prediction Analysis Review - beatles.ru
Phathom Pharmaceuticals Reports Strong Q2 Growth - TipRanks
Bullish Candlestick Pattern Forms in Phathom Pharmaceuticals Inc.Growth Focused Entry Plan Suggestions Issued - metal.it
Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth - MSN
Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals (PHAT) Gets a Buy from H.C. Wainwright - The Globe and Mail
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $17 - 富途牛牛
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $17 to $28 - 富途牛牛
Phathom 2025 Q2 Earnings Net Loss Narrows 17.1% - AInvest
Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Q2 2025: Unpacking Contradictions in Growth Strategies and Market Focus - AInvest
Phathom Pharmaceuticals Stock (PHAT) Opinions on Q2 2025 Earnings Report - Quiver Quantitative
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat - Investing.com Canada
Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations - Investing.com Australia
Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals shares rise 11.41% intraday after reporting Q2 revenue beating estimates. - AInvest
Phathom Pharmaceuticals (PHAT) Q2 Earnings: Revenue Surpasses Es - GuruFocus
Phathom Pharmaceuticals Q2 2025 Financial Results - TradingView
Phathom Pharmaceuticals' Strategic Restructuring and Market Position: A Pathway to Long-Term Value Creation in a Capital-Constrained Biopharma Landscape - AInvest
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Published on: 2025-08-04 08:41:19 - metal.it
Does Phathom Pharmaceuticals Inc. stock perform well during market downturnsOutstanding trading profits - Jammu Links News
Is Phathom Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
Is it the right time to buy Phathom Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
How does Phathom Pharmaceuticals Inc. generate profit in a changing economySkyrocketing investment returns - Jammu Links News
Should I hold or sell Phathom Pharmaceuticals Inc. stock in 2025Achieve impressive returns with smart timing - Jammu Links News
How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Unlock exclusive stock market insights - Jammu Links News
When is Phathom Pharmaceuticals Inc. stock expected to show significant growthInvest smarter with data-backed trading alerts - Jammu Links News
What is the dividend policy of Phathom Pharmaceuticals Inc. stockBuild wealth steadily with proven strategies - Jammu Links News
What catalysts could drive Phathom Pharmaceuticals Inc. stock higher in 2025Free Stock Market Real-Time Monitoring - Jammu Links News
Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News - 富途牛牛
Published on: 2025-08-01 16:17:13 - metal.it
Elliott Wave Theory Predicts Pullback in Phathom Pharmaceuticals Inc.Low Risk Picks for Daily Trading Released - metal.it
Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
Phathom Pharmaceuticals Inc (PHAT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
| Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
1.38%
0.27%
大文字化:
|
ボリューム (24 時間):